Literature DB >> 15143346

Omomyc expression in skin prevents Myc-induced papillomatosis.

L Soucek1, S Nasi, G I Evan.   

Abstract

Obligate sensitization to apoptosis provides a safeguard mechanism against the oncogenic potential of Myc. Omomyc is a mutant bHLHZip domain that sequesters Myc in complexes that are unable to bind to the E box recognition element and activate transcription but remain competent for transcriptional repression. Omomyc has the peculiar properties of reverting Myc-induced transformation of tissue culture cells and enhancing Myc proapoptotic function. Thus, Omomyc has the potential to act as a potent suppressor of Myc-induced oncogenesis. To validate the therapeutic potential of Omomyc in vivo, we targeted its expression to the adult suprabasal epidermis of Inv-c-MycER (TAM) transgenic mice which express a switchable form of the Myc protein in suprabasal cells. Activation of Myc induces rapid epidermal hyperplasia and papillomatosis. We show that Omomyc inhibits such Myc-induced papillomatosis, potentiating Myc-dependent apoptosis in a tissue in which it is usually strongly suppressed. Furthermore, Omomyc expression restores the normal keratinocyte differentiation program and skin architecture, both of which are otherwise disrupted by Myc activation. These findings indicate that it is possible to selectively enhance the intrinsic apoptotic pathway mediated by Myc and so quell its oncogenic action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15143346     DOI: 10.1038/sj.cdd.4401443

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  35 in total

Review 1.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

2.  An "-omycs" Toolbox to Work with MYC.

Authors:  Jonathan Whitfield; Laura Soucek
Journal:  Methods Mol Biol       Date:  2021

3.  Resetting cancer stem cell regulatory nodes upon MYC inhibition.

Authors:  Silvia Galardi; Mauro Savino; Fiorella Scagnoli; Serena Pellegatta; Federica Pisati; Federico Zambelli; Barbara Illi; Daniela Annibali; Sara Beji; Elisa Orecchini; Maria Adele Alberelli; Clara Apicella; Rosaria Anna Fontanella; Alessandro Michienzi; Gaetano Finocchiaro; Maria Giulia Farace; Giulio Pavesi; Silvia Anna Ciafrè; Sergio Nasi
Journal:  EMBO Rep       Date:  2016-11-16       Impact factor: 8.807

Review 4.  Cell metabolism: an essential link between cell growth and apoptosis.

Authors:  Emily F Mason; Jeffrey C Rathmell
Journal:  Biochim Biophys Acta       Date:  2010-09-08

5.  Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.

Authors:  Kwan-Young Jung; Huabo Wang; Peter Teriete; Jeremy L Yap; Lijia Chen; Maryanna E Lanning; Angela Hu; Lester J Lambert; Toril Holien; Anders Sundan; Nicholas D P Cosford; Edward V Prochownik; Steven Fletcher
Journal:  J Med Chem       Date:  2015-03-30       Impact factor: 7.446

6.  Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.

Authors:  Javier A Menendez; Tomás Alarcón; Jorge Joven
Journal:  Cell Cycle       Date:  2014-02-03       Impact factor: 4.534

Review 7.  MYC protein interactors in gene transcription and cancer.

Authors:  Diana Resetca; Cornelia Redel; Corey Lourenco; Peter Lin; Alannah S MacDonald; Roberto Ciaccio; Tristan M G Kenney; Yong Wei; David W Andrews; Maria Sunnerhagen; Cheryl H Arrowsmith; Brian Raught; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2021-06-29       Impact factor: 60.716

8.  Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Authors:  Laura Soucek; Jonathan R Whitfield; Nicole M Sodir; Daniel Massó-Vallés; Erika Serrano; Anthony N Karnezis; Lamorna Brown Swigart; Gerard I Evan
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

Review 9.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

10.  MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.

Authors:  Adlai R Grayson; Erica M Walsh; Michael J Cameron; Jernej Godec; Todd Ashworth; Jessica M Ambrose; Alexandra B Aserlind; Hongfang Wang; Gerard Evan; Michael J Kluk; James E Bradner; Jon C Aster; Christopher A French
Journal:  Oncogene       Date:  2013-04-22       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.